Two studies explore gender, language, and treatment setting as barriers in screening and patient care in lung cancer

October 23, 2017

TORONTO (October 23, 2017) -More people die of lung cancer than any other type of cancer, and two new studies from CHEST 2017 reveal disparities in lung cancer screening and care that may impact detection, as well as mortality and survival rates in the disease.

The first study from LaheyHospital and Medical Center in Burlington, Massachusetts, reviewed the Lahey lung cancer screening database for several characteristics, including smoking status, personal cancer history, lung cancer screening status, and time from initial contact to screening. Data were analyzed on patients who met either National Lung Screening Trial or National Comprehensive Cancer Network high-risk criteria, from January 2012 to March 2017.

They concluded that in the institution's lung cancer screening program, more female than male subjects were shown to meet high-risk criteria but had not completed a low-dose screening CT scan (LDCT). This highlights the need for further investigation into the potential interventions that can be taken to enhance lung screening in this particular patient population.

A second study out of Keck School of Medicine, University of Southern California, aimed to assess the effect of language spoken and of other demographic factors on delaying initiation of lung cancer care in patients at a public and private hospital system. In the multivariable analyses of 336 patients with non-small cell lung cancer, treatment at the public hospital was associated with delays in care; neither ethnicity nor primary language was associated with delays in care. The study demonstrates that even in a multi-ethnic population, the language barrier in and of itself does not seem to affect the interval from diagnosis to treatment.

Further results from the first study will be shared at CHEST Annual Meeting 2017 in Toronto on Wednesday, November 1, from 8:00 AM-8:15 AM at the Metro Toronto Convention Centre, Room 606. The study abstract can be viewed on the journal CHEST® website. Results from the second study will be shared at CHEST Annual Meeting 2017 in Toronto on Monday, October 30, from 3:45 PM-4:00 PMat the Metro Toronto Convention Centre, Room 603. The study abstract can be viewed on the journal CHEST® website.

CHEST 2017 is the 83rd annual meeting of the American College of Chest Physicians, held October 28-November 1, 2017, in Toronto, Ontario. The American College of Chest Physicians, publisher of the journalCHEST®, is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research, and team-based care. Its mission is to champion the prevention, diagnosis, and treatmentof chest diseases through education, communication, and research. It serves as an essential connection to clinical knowledge and resources for its 19,000+ members from around the world who provide patient care in pulmonary, critical care, and sleep medicine. For more information about CHEST 2017, visit, or follow CHEST meeting hashtag, #CHEST2017, on social media.

American College of Chest Physicians

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to